---
figid: PMC9630603__fbioe-10-1005051-g004
figtitle: Intersection of stem cell biology and engineering towards next generation
  in vitro models of human fibrosis
organisms:
- Mus musculus
- Rattus norvegicus
- Curcuma longa
- Homo sapiens
- Sus scrofa
organisms_ner:
- Homo sapiens
- Mus musculus
- Rattus norvegicus
- Sus scrofa
- Drosophila melanogaster
pmcid: PMC9630603
filename: fbioe-10-1005051-g004.jpg
figlink: /pmc/articles/PMC9630603/figure/F4/
number: F4
caption: Potential Therapeutic strategies for fibrosis. (A) Anti-fibrotic therapeutic
  strategies through inhibition of TGF-β pathway. (B) Therapeutic strategies through
  inhibition of RAS system. (C) Targeted anti-fibrotic therapeutic approach through
  biomaterial-based delivery. (D) Stem cell therapy with mesenchymal stromal cells
  for the treatment of fibrotic disease. (E) CAR T-cell therapy using engineered T
  cells for the treatment of fibrotic disease. (F) Gene therapy through mediating
  miRNA as a novel approach for anti-fibrosis treatment.
papertitle: Intersection of stem cell biology and engineering towards next generation
  in vitro models of human fibrosis.
reftext: Erika Yan Wang, et al. Front Bioeng Biotechnol. 2022;10:1005051.
year: '2022'
doi: 10.3389/fbioe.2022.1005051
journal_title: Frontiers in Bioengineering and Biotechnology
journal_nlm_ta: Front Bioeng Biotechnol
publisher_name: Frontiers Media S.A.
keywords: tissue engineeering | stem cell | fibrosis | disease modeling | organ on
  a chip (OCC) | biosensor | machine learning (ML)
automl_pathway: 0.8761334
figid_alias: PMC9630603__F4
figtype: Figure
redirect_from: /figures/PMC9630603__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9630603__fbioe-10-1005051-g004.html
  '@type': Dataset
  description: Potential Therapeutic strategies for fibrosis. (A) Anti-fibrotic therapeutic
    strategies through inhibition of TGF-β pathway. (B) Therapeutic strategies through
    inhibition of RAS system. (C) Targeted anti-fibrotic therapeutic approach through
    biomaterial-based delivery. (D) Stem cell therapy with mesenchymal stromal cells
    for the treatment of fibrotic disease. (E) CAR T-cell therapy using engineered
    T cells for the treatment of fibrotic disease. (F) Gene therapy through mediating
    miRNA as a novel approach for anti-fibrosis treatment.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TGFB1
  - TGFB2
  - TGFB3
  - ANGPT1
  - TM7SF2
  - ANGPT2
  - VPS51
  - ZFYVE9
  - SAR1A
  - SMAD3
  - SMAD2
  - SMAD4
  - MSC
  - SLC25A37
  - CASR
  - CXADR
  - PRKAR1A
  - SPG7
  - NR1I3
  - TRIM13
  - CXADRP1
  - CARTPT
  - Tgfb1
  - Ltbp1
  - Angpt1
  - Ang
  - Tm7sf2
  - Agt
  - Sar1a
  - Zfyve9
  - Smad3
  - Smad2
  - Smad4
  - Msc
  - Nr1i3
  - Casr
  - Cxadr
  - Rcvrn
  - Trim13
  - Arr3
  - Cartpt
  - ANG
  - dpp
  - gbb
  - put
  - mav
  - Sara
  - Smox
  - Med
  - msc
  - Scr
  - car
  - CarT
  - ACEI---ACE
---
